Topline results from the SURMOUNT-1 three-year study have shown that tirzepatide (Zepbound and Mounjaro) significantly reduced the risk of progression to type 2 diabetes by 94% among adults with pre-diabetes and obesity or overweight.

Additionally, treatment with tirzepatide resulted in sustained weight loss through the treatment period, with adults on the 15mg dose experiencing a 22.9% average decrease in body weight compared to 2.1% for placebo.

“Obesity is a chronic disease that puts nearly 900 million adults worldwide at an increased risk of other complications such as type 2 diabetes,” said Dr Jeff Emmick, Senior Vice President, Product Development, Lilly. “These data reinforce the potential clinical benefits of long-term therapy for people living with obesity and pre-diabetes.”

The drug was approved for chronic weight management in both the UK and US in late 2023. It was also shown to produce a mean reduction of up to 62.8% on the apnoea-hypopnea index (AHI) compared to placebo in the SURMOUNT-OSA Phase III clinical trials.

Results of the SURMOUNT-1 study

Tirzepatide was evaluated in 1,032 adults who had pre-diabetes at randomisation and obesity or overweight for a treatment period of 176 weeks, followed by a 17-week off-treatment period (193 weeks in total).

In a key secondary endpoint, tirzepatide led to a 94% reduction in risk of progression to type 2 diabetes compared to placebo up to week 176.

In an additional key secondary endpoint, tirzepatide (10mg and 15mg) led to statistically significant weight reduction compared to placebo in adults with pre-diabetes and obesity or overweight from baseline to week 176.

For the efficacy estimand, adults taking tirzepatide achieved average weight reductions of 15.4% (5mg), 19.9% (10mg) and 22.9% (15mg) compared to placebo (2.1%) at week 176.

For the treatment-regimen estimand, adults taking tirzepatide achieved average weight reductions of 12.3% (5mg), 18.7% (10mg) and 19.7% (15mg) compared to placebo (1.3%) at week 176.

During the 17-week off-treatment follow-up period, those who had discontinued from tirzepatide began to regain weight and had some increase in the progression to type 2 diabetes.

Tirzepatide is a GIP and GLP-1 receptor agonist, which works by activating the two hormone receptors. Nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake. Tirzepatide decreases calorie intake, stimulates insulin secretion and increases insulin sensitivity.

Diana Spencer, Senior Digital Content Editor, DDW